Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Decrease in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 489,100 shares, a decline of 10.6% from the January 15th total of 547,000 shares. Approximately 14.4% of the company’s shares are short sold. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is presently 0.3 days.

Allarity Therapeutics Stock Down 0.2 %

Shares of NASDAQ ALLR opened at $0.98 on Friday. Allarity Therapeutics has a 1-year low of $0.90 and a 1-year high of $264.00. The business has a 50-day moving average of $1.09 and a 200-day moving average of $2.14.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.